Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2008; 14(13): 2061-2064
Published online Apr 7, 2008. doi: 10.3748/wjg.14.2061
Published online Apr 7, 2008. doi: 10.3748/wjg.14.2061
Table 1 Patient’s data and indications for CE: Group A (fasting) and group B (additionally Prepacol®)
| Group A | Group B | P value | |
| Gender (w/m) | 13/13 | 10/16 | NS |
| Age (yr) | 54 ± 17 | 56 ± 20 | NS |
| Weight (kg) | 71 ± 15 | 79 ± 17 | NS |
| Length (cm) | 170 ± 10 | 171 ± 8 | NS |
| Indication | |||
| GI-bleeding | 17 (65%) | 19 (73%) | NS |
| Inflammatory bowel disease | 4 (15%) | 3 (12%) | NS |
| Miscellaneous | 5 (19%) | 4 (15%) | NS |
- Citation: Franke A, Hummel F, Knebel P, Antoni C, Böcker U, Singer MV, Löhr M. Prospective evaluation of small bowel preparation with bisacodyl and sodium phosphate for capsule endoscopy. World J Gastroenterol 2008; 14(13): 2061-2064
- URL: https://www.wjgnet.com/1007-9327/full/v14/i13/2061.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.2061